

European Society of Ophthalmology



Name: STELLA IOANA POPESCU
European Leadership Development Program Class of 2023-2025

Project Abstract

Title of Project: National Glaucoma Center

Purpose: Creating a National Glaucoma Center helps collect and provide data necessary for the coordination structures to develop specific glaucomatous disease rules.

Methods: Gathering data on the number of patients with this disease.
The main directions of treatment for the initial and subsequent stages.
Evidence of correlation between tonometric readings and glaucoma progression in compensated patients.
Elaboration of a standard for target intraocular pressure based on population groups and the particularities of our country.
Finding if there is a correlation between genetic potential and disease occurrence.
Establishing risk factors and their importance in the prevention of glaucomatous disease.
Develop a guide that explains the specific characteristics of glaucoma in our country.
We are establishing a correlation at the national level between various professional collectives.
Our objective is to organize profile meetings where specialists can exchange experience to refine their conclusions locally and internationally.
Realization of statistics in the field by age groups, risk factors, and family history of the particularity of glaucomatous disease in our country.
Realization of statistics regarding the therapeutic groups used.

Results: At this moment, the first version of the project, which was created in collaboration with several experts from the Romanian Society of Ophthalmology, is being prepared.

Conclusion: It is desired to obtain a National Glaucoma Center that addresses all ophthalmology centers in the country in order to facilitate the connection between the patient and the coordination structures of health policies in our country, the Ministry of Health, the Romanian Society of Ophthalmology, the Romanian Society of Glaucoma, Directorate of Public Health.
I appreciate that achieving these goals could also have an economic impact by improving and making the treatment of glaucoma more efficient. Compensation policies (iStent, Preserflo Microshunt, Hydrus, OMNI, STREAMLINE, Cypass, XEN, et al.) depend on the treatment's efficiency and tolerance.